NEW YORK / Oct 08, 2024 / Business Wire / Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, will release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows:
Live Call: 1.888.596.4244
Conference ID: 7768132
Webcast Link
The call will be archived and available on Oscar’s investor relations website (ir.hioscar.com) following November 7, 2024 for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is a leading healthcare technology company built around a full stack technology platform and a relentless focus on serving our members. We have been challenging the status quo in the healthcare system since our founding in 2012, and are dedicated to making a healthier life accessible and affordable for all. Oscar offers Individual & Family plans and health technology solutions that power the healthcare industry through +Oscar. Our technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 1.6 million members, as of June 30, 2024.
| Last Trade: | US$12.35 |
| Daily Change: | -0.10 -0.80 |
| Daily Volume: | 2,648,372 |
| Market Cap: | US$2.620B |
February 04, 2025 November 07, 2024 August 22, 2024 August 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
